Patient‐specific radiological protection precautions following Cs collagen embedded Cs‐131 implantation in the brain
Authors:
Open Access
- 15 September 2022
- journal article
- research article
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 23 (10) , e13776
Abstract
Objective: Cesium‐131 brachytherapy is an adjunct for brain tumor treatment, offering potential clinical and radiation protection advantages over other isotopes including iodine‐125. We present evidence‐based radiation safety recommendations from an initial experience with Cs‐131 brachytherapy in the resection cavities of recurrent, previously irradiated brain metastases.Methods: Twenty‐two recurrent brain metastases in 18 patients were resected and treated with permanent Cs‐131 brachytherapy implantation using commercially procured seed‐impregnated collagen tiles (GammaTile, GT Medical Technologies). Exposure to intraoperative staff was monitored with NVLAP‐accredited ring dosimeters. For patient release considerations, NCRP guidelines were used to develop an algorithm for modeling lifetime exposure to family and ancillary staff caring for patients based on measured dose rates.Results: A median of 16 Cs‐131 seeds were implanted (range 6–46) with median cumulative strength of 58.72U (20.64‐150.42). Resulting dose rates were 1.19 mSv/h (0.28–3.3) on contact, 0.08 mSv/h (0.01–0.35) at 30 cm, and 0.01 mSv/h (0.001–0.03) at 100 cm from the patient. Modeled total caregiver exposure was 0.91 mSv (0.16–3.26), and occupational exposure was 0.06 mSv (0.02–0.23) accounting for patient self‐shielding via skull and soft tissue attenuation. Real‐time dose rate measurements were grouped into brackets to provide close contact precautions for caregivers ranging from 1–3 weeks for adults and longer for pregnant women and children, including cases with multiple implantations.Conclusions: Radiological protection precautions were developed based on patient‐specific emissions and accounted for multiple implantations of Cs‐131, to maintain exposure to staff and the public in accordance with relevant regulatory dose constraints.Keywords
This publication has 20 references indexed in Scilit:
- Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomasJournal of Neurosurgery, 2019
- Clinical Outcomes of Large Brain Metastases Treated With Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Radiation Exposure and Safety Precautions Following 131Cs Brachytherapy in Patients with Brain TumorsHealth Physics, 2017
- Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic diseaseJournal of Neurosurgery, 2017
- Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastasesJournal of Neurosurgery, 2014
- Iodine-125 brachytherapy for brain tumours - a reviewRadiation Oncology, 2012
- EXPOSURE RATE CONSTANTS AND LEAD SHIELDING VALUES FOR OVER 1,100 RADIONUCLIDESHealth Physics, 2012
- Less-restrictive, patient-specific radiation safety precautions can be safely prescribed after permanent seed implantationBrachytherapy, 2010
- Preface, Executive Summary and GlossaryAnnals of the ICRP, 2007
- Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy.1998